Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
47
datasets available to search
ShareScore release 0.7.1
Dataset results
47 results for “GFAP”
Data from: Characterisation of GFAP-Expressing Glial Cells in the Dorsal Root Ganglion after Spared Nerve Injury
<p>This data pertain to the paper titled "Characterisation of GFAP-Expressing Glial Cells in the Dorsal Root Ganglion after Spared Nerve Injury " by Elena A. Konnova, Alexandru-Florian Deftu, Paul Chu Sin Chung, Marie Pertin, Guylène Kirschmann, Isabelle Decosterd and Marc R. Suter. The name of the data files correspond to the for each figure in the study. The data file in .csv format are organized so that they can easily be opened in R or other analysis language. To understand them and how they are labelled, it is advised to open the figure next to them and find the appropriate panel.</p><p>Here are included:</p><ul><li>the representative images of immunohistochemistry for GFAP, IBA1, Ki67, NeuN, ATF3, FABP7, GS, Cx43, Kir4.1, MBP, L1CAM in the dorsal root ganglia (DRG) of hGFAP-CFP mice after spared nerve injury (SNI).</li><li>the western blot images of DRG samples and FACS sorted CFP+ cells from the DRG of hGFAP-CFP mice after SNI</li><li>the voltage clamp data of GFAP+ cells from DRG of hGFAP-CFP mice after SNI</li></ul><p> </p>
Mode characterization and sensitivity evaluation of an ultra-high-frequency surface acoustic wave (UHF-SAW) resonator biosensor: application to the glial-fibrillary-acidic-protein (GFAP) biomarker detection
<p>Biosensors detect specific bio-analytes by generating a measurable signal from the interaction between the sensing element and the target molecule. Surface acoustic wave (SAW) biosensors offer unique advantages due to their high sensitivity, real-time response capability, and label-free detection. The typical SAW modes are the Rayleigh mode and the shear-horizontal mode. Both present pros and cons for biosensing applications and generally need different substrates and device geometries to be efficiently generated. This study investigates and characterizes ultra-high-frequency (UHF-) SAW resonator biosensors. It reveals the simultaneous presence of the two typical SAW modes, clearly separated in frequency, called slow and fast. The two modes are studied by numerical simulations and biosensing experiments with the glial-fibrillary-acidic-protein (GFAP) biomarker. The slow mode is generally more sensitive to changes in surface properties, such as temperature and mass changes, by a factor of about 1.4 with respect to the fast mode.</p>
Time course and diagnostic utility of NfL, tau, GFAp, and UCH-L1 in subacute and chronic TBI
<p><strong>Objective:</strong> To determine whether neurofilament light (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin C-terminal hydrolase-L1 (UCH-L1) measured in serum relate to traumatic brain injury (TBI) diagnosis, injury severity, brain volume, and diffusion tensor imaging (DTI) measures of traumatic axonal injury (TAI) in patients with TBI.</p> <p><strong>Methods:</strong> Patients with TBI (n = 162) and controls (n = 68) were prospectively enrolled between 2011 and 2019. Patients with TBI also underwent serum, functional outcome, and imaging assessments at 30 (n=30), 90 (n=48), and 180 (n=59) days, and 1 (n=84), 2 (n=57), 3 (n=46), 4 (n = 38), and 5 (n = 29) years after injury.</p> <p><strong>Results:</strong> At enrollment, patients with TBI had increased serum NfL compared to controls (p < 0.0001). Serum NfL decreased over the course of 5 years but remained significantly elevated compared to controls. Serum NfL at 30 days distinguished patients with mild, moderate, and severe TBI from controls with an area under the receiver-operating characteristic curve (AUROC) of 0.84, 0.92, and 0.92, respectively. At enrollment, serum GFAP was elevated in patients with TBI compared to controls (p < 0.001). GFAP showed a biphasic release in serum, with levels decreasing during the first 6 months of injury but increasing over the subsequent study visits. The highest AUROC for GFAP was measured at 30 days, distinguishing patients with moderate and severe TBI from controls (both 0.89). Serum tau and UCH-L1 showed weak associations with TBI severity and neuroimaging measures. Longitudinally, serum NfL was the only bio- marker that was associated with the likely rate of MRI brain atrophy and DTI measures of progression of TAI.</p> <p><strong>Conclusions:</strong> Serum NfL shows greater diagnostic and prognostic utility than GFAP, tau, and UCH-L1 for subacute and chronic TBI.</p> <p><strong>Classification of evidence:</strong></p> <p>This study provides Class III evidence that serum NfL distinguishes patients with mild TBI from healthy controls.</p>
Time course and diagnostic utility of NfL, tau, GFAp, and UCH-L1 in subacute and chronic TBI
Open the record for dataset details and reuse information.
Data from: Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD
Open the record for dataset details and reuse information.
CX3CR1-Fractalkine Dysregulation Affects Retinal GFAP Expression, Inflammatory Gene Induction, and LPS Response in a Mouse Model of Hypoxic Retinopathy
GEO Series GSE276207. Mus musculus. 18 samples. Type: Expression profiling by high throughput sequencing.
Region specific astrocyte response to mutant GFAP in Alexander disease model mice during postnatal development.
GEO Series GSE198817. Mus musculus. 18 samples. Type: Expression profiling by high throughput sequencing.
scRNA-seq analysis of SHH medulloblastomas in Gfap-Cre/SmoM2 mice treated with CT-179 or Pox-resiquimod
GEO Series GSE233519. Mus musculus. 1 samples. Type: Expression profiling by high throughput sequencing.
Genetic modifiers of GFAP expression in mouse models of Alexander disease
GEO Series GSE197044. Mus musculus. 16 samples. Type: Expression profiling by high throughput sequencing.
RNAseq analysis of FACS-isolated astrocytes from the striatum of 11-14 month-old knock-in Hdh140 mice after astrocyte-targeted expression of GFAP or JAK2ca
GEO Series GSE171141. Mus musculus. 11 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide analysis of the transcriptional profile of astrocytes across EAE by CNS region in Gfap-Cre;Ribotag(f/f) mice uisng Ribotag immunoprecipitation.
GEO Series GSE130118. Mus musculus. 40 samples. Type: Expression profiling by high throughput sequencing.
Hippocampal gene expression in the GFAP-R237H rat model of Alexander disease at early and late stages of disease
GEO Series GSE278645. Rattus norvegicus. 32 samples. Type: Expression profiling by high throughput sequencing.
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
ClinicalTrials.gov study NCT04201470. IPD Sharing: NO. Countries: 1. Publications: 0.
Serum GFAP and UCHL1: Evaluation of Their Predictive Value for SAH
ClinicalTrials.gov study NCT06581757. IPD Sharing: NO. Countries: 1. Publications: 0.
Neuropathy and Anti-GFAP Antibodies
ClinicalTrials.gov study NCT05742087. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery
ClinicalTrials.gov study NCT06899971. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
ClinicalTrials.gov study NCT04860947. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Association Between Changes of GFAP After Surgery and Postoperative Delayed Cognitive Recovery
ClinicalTrials.gov study NCT03683537. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
ClinicalTrials.gov study NCT05352971. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
ClinicalTrials.gov study NCT03981003. IPD Sharing: NO. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.